MOUNTAIN VIEW, Calif., May 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Marco F. Rosa to the newly created position of Vice President of Human Resources.
Mr. Rosa brings over 20 years of human resources experience to the Company. Most recently, Mr. Rosa worked at Carl Zeiss Meditec, Inc. as Vice President of Worldwide Human Resources, a position he had held since May of 2002. He was an integral part of the senior management team overseeing the company's growth and the commercial launch of several ophthalmology and surgical microscopy devices. Prior to Carl Zeiss, Mr. Rosa served as Vice President, Human Resources at COR Therapeutics, Inc., building the development and commercial organizations and launching Integrilin(R) in the cardiovascular angioplasty market. Before joining COR, Mr. Rosa held senior human resources and key administrative management positions with ReplayTV, Inc., Genelabs Technologies, Inc., and Sony Electronics Inc. Prior to 1990, Mr. Rosa held similar management positions with the General Electric Company where he started his career in human resources.
"I'm pleased to have Marco join our management team and help to develop the future of the company as we continue our late-stage product development and move toward potential commercialization," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "Marco brings unique company building expertise to our efforts to develop improved therapies for children and adults who suffer from diseases that we believe are not adequately treated by currently available medicines."
In addition to his extensive human resources experience, Mr. Rosa served as a Captain in the BioMedical Corps of the United States Air Force. Mr. Rosa received his B.A. degree in Psychology from St. Michael's College and his M.A. degree in Counseling Psychology from New York University.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The Company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
|SOURCE MAP Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved